Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefuroxime PK/PD target attainment in adult general ward patients with different renal function
NL-OMON52078Completed
- Sponsor
- Noordwest Ziekenhuisgroep
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cefuroxime in bacterial disease (2 arms), sponsored by Noordwest Ziekenhuisgroep. Primary endpoint: PK-PD target attainment of 50%T>MIC in first 24 hours. Started Jan 2022; status: completed.
02
Drugs
cefuroxime
03
Conditions
bacterial disease
Beyond the preview
Go deeper on NL-OMON52078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52078.